Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.41 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13617435 | 0.91 | HDAC6 (0.46) | CPB2CPB1AKT1 | |
| SCHEMBL6324267 | 0.89 | ACE (0.52) | CPB2CPB1ACEPTPN1PPARA | |
| SCHEMBL215179 | 0.84 | ACE (0.56) | ACEPTPN1PPARAPPARGITGB3 | |
| SCHEMBL29573143 | 0.84 | ACE (0.56) | ACEPTPN1PPARAPPARGITGB3 | |
| SCHEMBL29613833 | 0.84 | ACE (0.56) | ACEPTPN1PPARAPPARGITGB3 | |
| SCHEMBL268002 | 0.84 | ACE (0.56) | ACEPTPN1PPARAPPARGITGB3 | |
| SCHEMBL215178 | 0.84 | ACE (0.56) | ACEPTPN1PPARAPPARGITGB3 | |
| SCHEMBL6329225 | 0.84 | CPB2 (0.64) | CPB2CPB1ACEPTPN1PPARA | |
| SCHEMBL3429311 | 0.83 | ACE (0.56) | CPB2ACEPTPN1PPARAPPARG | |
| SCHEMBL17642069 | 0.83 | ACE (0.56) | CPB2ACEPTPN1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| US-6949577-B2 | Pharmaceuticals | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236420-A1 | Pharmaceuticals | BDKRB1, TFPI, SERPINE1 | CPB2 167/4885CPB1 181/4885ACE 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.